Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Genital Neoplasms, Female × fosaprepitant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 11 Nausea 4 Neoplasms 3 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Testicular Neoplasms 1 Sarcoma 1 Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1 Ovarian Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Gynecologic Cancer 1 Genital Neoplasms, Female 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

pembrolizumab 3 Educational Status 3 Surveys and Questionnaires 2 Standard of Care 2 Radiotherapy 2 Palliative Care 2 Paclitaxel 2 Nivolumab 2 Methods 2 Interviews as Topic 2 Gemcitabine 2 Early Intervention, Educational 2 Carboplatin 2 temsirolimus 1 rucaparib 1 relacorilant 1 olaparib 1 nilotinib 1 liposomal doxorubicin 1 lenvatinib 1 fosaprepitant 1 atezolizumab 1 argatroban 1 anlotinib 1 Topotecan 1 Thrombopoietin 1 Therapeutic Touch 1 Surgical Procedures, Operative 1 Practice Guidelines as Topic 1 Pemetrexed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01074697 2015-04-24

GAND-emesis

Odense University Hospital

Phase 3 Completed

Genital Neoplasms, Female, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡